small molecule

MESALAMINE

MESALAMINE

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameMESALAMINE
Active ingredientMESALAMINE
Strength1GM
Dosage formSUPPOSITORY
RouteRECTAL
ModalitySmall molecule
FDA approvalJanuary 2020
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.